RETROPERITONEAL LIPOSARCOMA TREATMENT MARKET ANALYSIS

Leading Companies

Retroperitoneal liposarcoma Treatment Market – Competitor Landscape

Increasing regulatory approvals by the U.S. FDA for various products manufactured by large companies is expected to boost the overall growth of the retroperitoneal liposarcoma treatment market. For instance, in 2015, the U.S. FDA granted priority review for the New Drug Application (NDA) for YONDELIS (trabectedin), manufactured by Janssen Research & Development, LLC to treat patients with advanced soft tissue sarcoma (STS), which includes liposarcoma and leiomyosarcoma subtypes in 77 countries, within North America, Europe, South America, and Asia. Furthermore, in 2016, Eisai Co., Ltd. received the approval in Japan for its in-house developed anticancer agent Halaven (eribulin mesylate) for the treatment of patients suffering from soft tissue sarcoma.

Market players operating in the global retroperitoneal liposarcoma treatment market include Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc, Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories, and Zydus Cadila.